A new experimental GLP-1 pill could make it easier for people with type 2 diabetes to access treatments that help control blood sugar and support weight loss.
At the American Diabetes Association's Scientific Sessions, Mass General Brigham researcher Vanita Aroda, MD, presented results from SOLSTICE, a phase 2b randomized, placebo-controlled clinical trial evaluating the oral GLP-1 receptor agonist elecoglipron. The findings were published simultaneously in The Lancet.
The study found that elecoglipron significantly lowered blood glucose levels and reduced body weight in people with type 2 diabetes. Researchers say the results highlight the growing potential of oral GLP-1 medications to address some of the limitations associated with current treatment options.
Oral GLP-1 Treatment Shows Promise
"Our study's findings underscore the expanding potential of oral GLP-1 receptor agonists for people with type 2 diabetes," said Aroda, who serves as Director of Diabetes Clinical Research in the Division of Endocrinology, Diabetes & Hypertension within the Mass General Brigham Department of Medicine.
